Jevtana Kit
Product Images NDC 0024-5824

5 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Jevtana (NDC 0024-5824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 01)

Chemical Structure (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 01)
Chemical structure of cabazitaxel, the active ingredient in Jevtana, shown as a complex molecular diagram with multiple rings, oxygen atoms, and functional groups consistent with its taxane class.*
FDA Label Image

Figure 1 (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 02)

Figure 1 (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 02)
A survival curve chart comparing overall survival proportions over 30 months between two groups: mitoxantrone + prednisone (solid blue line with filled circles) and cabazitaxel + prednisone (red line with open circles). The x-axis represents time in months, and the y-axis shows the proportion of overall survival. A table below the chart lists the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 2 (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 03)

Figure 2 (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 03)
A Kaplan-Meier survival curve chart showing the probability of overall survival (%) over time in months. Two treatment groups, CBZ20+PRED and CBZ25+PRED, are compared with corresponding censored data points, accompanied by a table indicating the number of patients at risk at various months.*
FDA Label Image

Figure 3 (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 04)

Figure 3 (De3d9c26 572b 4ea4 9b2d Dd58a2b3e8fa 04)
A Kaplan-Meier survival curve chart showing rPFS (months) for two treatment groups in an ITT population: cabazitaxel and enzalutamide or abiraterone. The chart includes a plot of survival estimates over time in months with number of patients at risk displayed below the x-axis. Censored data points are marked on the curves.*
FDA Label Image

Principal Display Panel (Kit Carton)

Principal Display Panel (Kit Carton)
Jevtana (cabazitaxel) Injection 60 mg / 1.5 mL kit packaging label. The carton includes one single-dose Jevtana vial and one single-dose diluent vial. Label indicates the product is for intravenous infusion only after a two-step dilution process. Labeler is Sanofi-Aventis U.S. LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.